First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel

Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Gupta N, Hatoum H, Dy GK
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/130901e4e4d949f2b1c485b37d7dfbeb
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:130901e4e4d949f2b1c485b37d7dfbeb
record_format dspace
spelling oai:doaj.org-article:130901e4e4d949f2b1c485b37d7dfbeb2021-12-02T06:31:59ZFirst line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel1178-2013https://doaj.org/article/130901e4e4d949f2b1c485b37d7dfbeb2013-12-01T00:00:00Zhttp://www.dovepress.com/first-line-treatment-of-advanced-non-small--cell-lung-cancer-ndash-spe-a15371https://doaj.org/toc/1178-2013 Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of cases. Paclitaxel has a broad spectrum of activity against various malignancies, including NSCLC. Paclitaxel is poorly soluble in water and thus, until recently, its commercially available preparations contained a non-ionic solvent Cremophor EL®. Cremophor EL® improves the solubility of paclitaxel and allows its intravenous administration. However, certain side-effects associated with paclitaxel, such as hypersensitivity reactions, myelosuppression, and peripheral neuropathy, are known to be worsened by Cremophor®. Nanoparticle albumin-bound paclitaxel ([nab-paclitaxel] ABRAXANE® ABI-007) is a new generation formulation of paclitaxel that obviates the need for Cremophor®, resulting in a safer and faster infusion without requiring the use of premedications to avoid hypersensitivity. Albumin-binding receptor-mediated delivery and lack of sequestering Cremophor® micelles allow higher intratumoral concentration of pharmacologically active paclitaxel. Multiple clinical trials have demonstrated a superior tolerability profile of nab-paclitaxel in comparison to solvent-bound paclitaxel (sb-paclitaxel). A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. This trial highlights the weekly nab-paclitaxel combination as an alternate treatment option for NSCLC, with higher response rate in squamous cell NSCLC and longer survival in elderly patients. This review will focus on the properties of nab-paclitaxel and its use in the first line treatment of NSCLC.Keywords: ABI-007, Abraxane, nab-paclitaxel, lung neoplasmsGupta NHatoum HDy GKDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 209-221 (2013)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Gupta N
Hatoum H
Dy GK
First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
description Neha Gupta, Hassan Hatoum, Grace K DyDepartment of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAAbstract: Lung cancer is the leading cause of cancer mortality worldwide in both men and women. Non-small-cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for more than 80% of cases. Paclitaxel has a broad spectrum of activity against various malignancies, including NSCLC. Paclitaxel is poorly soluble in water and thus, until recently, its commercially available preparations contained a non-ionic solvent Cremophor EL®. Cremophor EL® improves the solubility of paclitaxel and allows its intravenous administration. However, certain side-effects associated with paclitaxel, such as hypersensitivity reactions, myelosuppression, and peripheral neuropathy, are known to be worsened by Cremophor®. Nanoparticle albumin-bound paclitaxel ([nab-paclitaxel] ABRAXANE® ABI-007) is a new generation formulation of paclitaxel that obviates the need for Cremophor®, resulting in a safer and faster infusion without requiring the use of premedications to avoid hypersensitivity. Albumin-binding receptor-mediated delivery and lack of sequestering Cremophor® micelles allow higher intratumoral concentration of pharmacologically active paclitaxel. Multiple clinical trials have demonstrated a superior tolerability profile of nab-paclitaxel in comparison to solvent-bound paclitaxel (sb-paclitaxel). A recent Phase III trial compared the effects of weekly nab-paclitaxel in combination with carboplatin versus sb-paclitaxel in combination with carboplatin given every 3 weeks for first line treatment of NSCLC. This trial highlights the weekly nab-paclitaxel combination as an alternate treatment option for NSCLC, with higher response rate in squamous cell NSCLC and longer survival in elderly patients. This review will focus on the properties of nab-paclitaxel and its use in the first line treatment of NSCLC.Keywords: ABI-007, Abraxane, nab-paclitaxel, lung neoplasms
format article
author Gupta N
Hatoum H
Dy GK
author_facet Gupta N
Hatoum H
Dy GK
author_sort Gupta N
title First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
title_short First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
title_full First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
title_fullStr First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
title_full_unstemmed First line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
title_sort first line treatment of advanced non-small-cell lung cancer – specific focus on albumin bound paclitaxel
publisher Dove Medical Press
publishDate 2013
url https://doaj.org/article/130901e4e4d949f2b1c485b37d7dfbeb
work_keys_str_mv AT guptan firstlinetreatmentofadvancednonsmallcelllungcancerndashspecificfocusonalbuminboundpaclitaxel
AT hatoumh firstlinetreatmentofadvancednonsmallcelllungcancerndashspecificfocusonalbuminboundpaclitaxel
AT dygk firstlinetreatmentofadvancednonsmallcelllungcancerndashspecificfocusonalbuminboundpaclitaxel
_version_ 1718399859811155968

Ejemplares similares